SCHEMBL5021076

SCHEMBL5021076

CC(=O)C(C)C(C(C)=O)C(=O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.58
CTSB P07858 1/20 0.49
ELANE P08246 1/20 0.48
TDP1 Q9NUW8 2/20 0.47
MAPK1 P28482 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 1/20 0.44
HCAR2 Q8TDS4 1/20 0.44
ATM Q13315 1/20 0.43
CDC25B P30305 1/20 0.43
ALOX15 P16050 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16994619 0.87 ALDH1A1 (0.58) ALDH1A1CTSBELANETDP1MAPK1
SCHEMBL12141748 0.84 ALDH1A1 (0.54) ALDH1A1CTSBELANETDP1MAPK1
SCHEMBL19105358 0.82 CTSB (0.61) ALDH1A1CTSBELANETDP1MAPK1
SCHEMBL12640200 0.82 ALDH1A1 (0.64) ALDH1A1CTSBTDP1MAPK1L3MBTL1
SCHEMBL2928989 0.81 ALDH1A1 (0.63) ALDH1A1CTSBELANETDP1MAPK1
SCHEMBL19105400 0.79 ALDH1A1 (0.56) ALDH1A1CTSBELANETDP1MAPK1
SCHEMBL2068112 0.79 CTSB (0.58) ALDH1A1CTSBELANETDP1MAPK1
SCHEMBL998609 0.79 CTSB (0.58) ALDH1A1CTSBELANETDP1MAPK1
SCHEMBL998611 0.79 CTSB (0.58) ALDH1A1CTSBELANETDP1MAPK1
SCHEMBL7060350 0.79 ALDH1A1 (0.53) ALDH1A1CTSBELANETDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178697-B2 Method for the preparation of atorvastatin and intermediates used therein CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2012-05-15 US disclosed
US-20110015407-A1 METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015407-A1 METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN HMGCR, PCSK9, CETP ALDH1A1 1340/4885CTSB 1662/4885ELANE 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.